Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: F. Stephen Hodi, Mario Sznol, Harriet M. Kluger, David F. McDermott, Richard D. Carvajal, Donald P. Lawrence, Suzanne Louise Topalian, Michael B. Atkins, John D. Powderly, William Howard Sharfman, Igor Puzanov, David C. Smith, Philip D. Leming, Evan J. Lipson, Janis M. Taube, Robert Anders, Christine E. Horak, Georgia Kollia, Ashok Kumar Gupta, Jeffrey Alan Sosman
Institutions: Dana-Farber Cancer Institute, Yale Cancer Center, Beth Israel Deaconess Medical Center, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Carolina BioOncology Institute, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of Michigan, Christ Hospital, Bristol-Myers Squibb (United States), Vanderbilt University Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2286032567